The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Medical School
- Nano Medicine
- Parkinson's disease
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- The Anatomy of a Perfect Holiday Board – D Magazine
- Anatomy of a search: As rescue workers search for missing boaters near Oregon, they’re also trying to find closure – SaukValley.com
- Anatomy gym to open in Coconut Grove – The Real Deal
- Greys Anatomy Contributed To Public Awareness Of Sexual Assault Report – Deadline
- ‘The feeling I had after that game was heartbreaking’ – The anatomy of a Leinster final shock – Independent.ie
- verywellfit com
- is this true Allergens in plants produced as a result of genetic engineering can be transferred to human as if humans eat that allergic food
- anti anxiety & nootropics
- Cul3 anxiety
- learned immortality medical
- indexof/ Green Room
- stephen hahn stance on stem cells
- Medical genetics wikipedia
- scarieteen com/glossary#partner
|Search Immortality Topics:|
Category Archives: Biotechnology
Review of George Estreich, ‘Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves’ (opinion) – Inside Higher Ed
A few months ago, I attended a forum on the politics and economics of disability. My impression was that the audience consisted mainly of people with disabilities -- an impression that has changed with time. Whatever the proportions may actually have been, my judgment was probably skewed by self-consciousness, and not just the usual awkwardness of finding a seat after the presentation was well underway. It had taken root long before I got to the room.
"Able-bodied" and "disabled" are categories that function in society at large as necessary and common-sensical, and they are weighted such that the first is posited as normal and predominant, and as such effectively invisible, while the other is an exceptional condition, making it, oddly, both conspicuous and ignorable as circumstances may dictate. With hindsight I am not at all sure more people at the talk had wheelchairs or canes than were present at other talks I attended at the conference. Besides, not every disability involves such a clear marker.
But since disability itself was the topic of the hour, the fact that I did not need any such assistance registered much more sharply than it ordinarily would. Eyeglasses didn't count. Experiential norms prevailing outside the room were not taken for granted, as became even more clear following the speaker's presentation. A number of people pointed out that no American Sign Language interpreter was present. Somehow I had not noticed. Not noticing certain things is a luxury you generally aren't even aware of enjoying.
As binary oppositions go, "able-bodied/disabled" proves much less stable than it appears. It's not just that the most gifted athlete or graceful dancer may be one bullet or automobile accident away from an irrevocable change in status. As mentioned, wearing glasses allows me to function as fully able, but they are a prosthesis for the lenses in my eyes, quite as much a wheelchair is for a paraplegic's legs. And the process of aging has a way of erasing the bright line between ability and its malfunctions. Time is not on the side of the able-bodied. With aging, the binary opposition runs right through the brain, so to speak. Jokes about "having a senior moment" acknowledge (and deflect) this reality. Our long-term command of the powers of attention and memory is contingent at best.
One of the things the reader can take away from George Estreich's Fables and Futures: Biotechnology, Disability, and the Stories We Tell Ourselves (MIT Press) is a heightened sense of how damaging it can be to think of "the disabled" in terms of a distinction between "us" and "them." An instructor in writing at Oregon State University, Estreich is also the author of The Shape of an Eye: A Memoir, about raising his daughter Laura, who has Down syndrome. I haven't read it, but she reappears throughout Fables and Futures without that making the book a memoir, exactly.
"Writing about Laura has its complications," Estreich notes. "For each sentence, I could add a page of narrative caveats, a fine print to govern the legal interpretation of anecdote: 'This positive description is not meant to inspire Though the author has strong opinions on a range of social issues, he declines to weaponize his daughter in their service. Laura is not an example in an argument She is a person, and by describing her the author intends to suggest what she is like and raise questions about the world she enters. This work is related to, yet different from, his work as a parent, which is to help her find, in every sense, her place.' Behind these caveats is the wish to control interpretation, and behind that vain hope is, in no particular order, a writer's ego, a father's protectiveness, and a deep familiarity with the average Internet comment section."
That is quite a few knives to juggle at the same time. And the list does not even include the issue on which Estreich concentrates here: the advancing biotechnology of prenatal testing and genetic editing. The book is a sort of intellectual travelogue, the author thinking his way across a landscape that is changing faster than it can be captured in concepts. When he attends an event in New Orleans that doubles as a professional conference for genetic counselors and a trade show for biotech companies, he notes, "The uneasy tension between old and new brought on by biotech: the more artifice the project requires, the more its advocates retail images of naturalness and purity." The quest to render the woolly mammoth "de-extinct" coexists with strong an implicit and largely unacknowledged strain of 21st-century eugenics.
Given the murderous consequences of one especially vehement form, we tend to think of eugenics as prone to goose-stepping. But a tangent from the memory of his daughter's participation in a county fair leads Estreich back to the era of Better Babies and Fitter Families contests at Midwestern state fairs, in which whole families underwent exams and answered questionnaires to determine which was freest from inherited defects. "If human improvement is on stage," he writes, "disability-based metaphors are usually skulking in the wings."
The author's worry -- which is also a father's worry -- concerns the possible cascade of effects of "our rapidly increasing, fine-grained knowledge of genetic variation." A culture that takes technological development as inevitable is dangerous enough, to itself and others, without having the option of decision making that "invoke[s] abnormality, a word capacious enough to hold everything and everyone considered different and undesirable." Estreich is uncommonly adept at presenting both experiences and ideas in layers, without the structure itself becoming either unmanageable or distracting. Anyone who reads it should expect the wheels in their head to keep spinning for a while afterward.
Cambridge-based biopharma company Epizyme has secured $100 million in private equity funding, according to company database Crunchbase, topping the citys recent funding headlines. The cash infusion was announced Nov. 7 and financed by Royalty Pharma.
According to its Crunchbase profile, "Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future."
The 13-year-old company has raised five previous funding rounds, including a $10 million post IPO equity round in 2014.
The round brings total funding raised by Cambridge companies in health care over the past month to $391 million, an increase of $181 million from the month before. The local health care industry has seen 91 funding rounds over the past year, capturing a total of $3.4 billion in venture funding.
In other local funding news, biopharma company EGenesis announced a $100 million Series B funding round on Nov. 7, led by Fresenius Medical Care.
According to Crunchbase, "EGenesis designs xenotransplantation for the benefit of human health. Its technology helps transform xenotransplantation into a medical procedure, enabling clinical researchers to address the global organ shortage."
Founded in 2014, the company has raised two previous rounds, including a $38 million Series A round in 2017.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
Global Biotechnology Market North America Is Expected To Account For Higher Market Share Of More Than 45% Driven By Increasing Investment In Us On…
Global Biotechnology Market is expected to grow at a CAGR of 14% to reach US$ 1,254.1 million in 2024. The growth is coupled with rising demand of modern and innovative technologies such as DNA sequencing, recombinant technology, fermentation, tissue engineering. Further, rising demand for food to meet the need of ever increasing population and scarce availability of non-renewable natural resources also expected to drive the biotechnology market. Application of Genetic engineering and Genetic Modification (GM) processes to agricultural food products also expected to drive the business growth. Furthermore, decreasing prices of DNA sequencing technologies will encourage R&D activities to better understand genetic variations and develop therapeutic solutions.
REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/10844
Moreover, development of novel techniques and their implementation by the organisation by collaborating with the other participants will drive the Global Biotechnology Market. Further, increasing demand for therapeutic and diagnostic solutions on principles of red biotechnology, DNA sequencing, and recombinant technology is expected to drive the Global Biotechnology Market through 2024. Increasing prevalence of diseases such as hepatitis B, cancer, and other orphan disorders is also expected to fuel demand in the forecast period.
In 2017, North America dominated the overall market. The market growth is driven by the increasing R&D investments relating to new drug discovery and development. U.S. held highest market in North America due to increasing level of per capita spending on healthcare than other countries and has a high growth rate amongst other countries. According to the estimates published by OECD Health Statistics in 2014, it has been estimated that in 2012, U.S. spent nearly 16.9% of its GDP towards healthcare expenditure, which is the highest. The fact supports the estimated share of Global Biotechnology Market.
Asia Pacific is expected to have higher growth rate in the forecast period owing to the presence of patient awareness, rapidly improving healthcare infrastructure, and rising healthcare expenditure levels in the emerging markets. Global Biotechnology Market include the developing economies of China and India.
In 2017, nanobiotechnology held the highest market share. The Global Biotechnology Market growth is driven by fermentation and cell-based assay segments owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.
DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/10844
Global Biotechnology Market
Market Segmentation By Technologyo DNA Sequencingo Nanobiotechnologyo Tissue engineering and Regenerationo Fermentationo Cell Based Assayo PCR Technologyo Chromatography Marketo Others
By Applicationso Healtho Food & Agricultureo Natural Resources & Environmento Industrial Processingo Bioinformaticso Others
The above data will be provided for following regions/countries from 2013-2024 (USD Million)
North Americao U.S.o Canada
Europeo Germanyo UKo Franceo Spaino Italy
Asia Pacifico Chinao Indiao Japano Australia
Latin Americao Argentinao Brazilo Mexico
Middle East and Africao South Africao Saudi Arabia
MAJOR TOC OF THE REPORT
Chapter One: Biotechnology Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Biotechnology Market Competition, by Players
Chapter Four: Global Biotechnology Market Size by Regions
Chapter Five: North America Biotechnology Revenue by Countries
Chapter Six: Europe Biotechnology Revenue by Countries
Chapter Seven: Asia-Pacific Biotechnology Revenue by Countries
Chapter Eight: South America Biotechnology Revenue by Countries
Chapter Nine: Middle East and Africa Revenue Biotechnology by Countries
Chapter Ten: Global Biotechnology Market Segment by Type
Chapter Eleven: Global Biotechnology Market Segment by Application
Chapter Twelve: Global Biotechnology Market Size Forecast (2019-2026)
Browse Full Report with Facts and Figures of Biotechnology Market Report at: https://www.maximizemarketresearch.com/market-report/global-biotechnology-market/10844/
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Name: Lumawant Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Contact: +919607065656/ +919607195908
Biotechnology Algae Cultivation Process (Micro Algae) Market 2019: Growth, Latest Trend Analysis and Forecast 2025 – Techi Labs
According to a latest report published by Global Marketers Biz named as Quartz Tubing Market offers data for the forecast period 2019-2024. A comprehensive research updates and data which includes following key aspects for the global Quartz Tubing Market in terms of volume and revenue Visitor Demographics, Facility Size, Demand & Growth Opportunities, Global Industry Forecast Analysis and Revenue Source.
The Quartz Tubing Market report offers in-depth analysis and insights into developments impacting businesses and enterprises on global & regional level. A detailed breakdown of key trends, drivers, restraints, and opportunities influencing revenue growth is presented in this research report. This study focuses on the global Quartz Tubing market by share, volume, value, and regional appearance along with the types and applications.
Request a free sample report on Quartz Tubing market @https://www.globalmarketers.biz/report/chemicals-and-materials/global-quartz-tubing-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130825#request_sample
Please Note :This Report can be dispatched within 24 Hours
Key Players of Quartz Tubing Report are:
Momentive (US)Heraeus (DE)QSIL (DE)SAINT-GOBAIN (FR)Shin-Etsu (JP)Ohara (JP)Atlantic Ultraviolet (US)TOSOH (JP)Raesch (DE)Pacific Quartz (CN)Guolun Quartz (CN)Dongxin Quartz (CN)Fudong Lighting (CN)Dong-A Quartz (CN)Yuandong Quartz (CN)Zhuoyue Quartz (CN)Lanno Quartz (CN)Ruipu Quartz (CN)
Market is Segmented into below points:
Market by Type/Products:
Transparent quartz tubeOpaque and translucent tubes
Market by Application/End-Use:
The segment applications includingLightingSemiconductorIndustrial ApplicationsPhotovoltaic
Market by Region:
For Discount on this report please visit @ https://www.globalmarketers.biz/report/chemicals-and-materials/global-quartz-tubing-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130825#inquiry_before_buying
Some of the major areas of this report:
Request for Customized Report:https://www.globalmarketers.biz/report/chemicals-and-materials/global-quartz-tubing-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130825#inquiry_before_buying
About Global Marketers Biz:
Global Marketers is a research eye which discovers the syndicate, custom and consulting research needs. The company surpasses in catering to the research requirements of commercial, industrial and all other business enterprises. Surgical market analysis followed by Comprehensive research methodology will drive the businesses in planning & reshaping the business schemes and the growth of industry. The company also offers research reports related to chemical, healthcare, technology, automobile and several other sectors. This is the trustworthy brand when talked about quality survey and highly reachable to customer requirements of any industry situated across the globe.
For any additional questions get in touch with,
Mr. Alex White
Phone number: +1(617)2752538
Intrexon Corporation (XON) vs. MobileIron, Inc. (MOBL): Comparing the Biotechnology Industrys Most Active Stocks – E Globalist
Intrexon Corporation (NASDAQ:XON) shares are down more than -14.22% this year and recently increased 2.56% or $0.14 to settle at $5.61. MobileIron, Inc. (NASDAQ:MOBL), on the other hand, is up 5.01% year to date as of 11/14/2019. It currently trades at $4.82 and has returned -1.23% during the past week.
Intrexon Corporation (NASDAQ:XON) and MobileIron, Inc. (NASDAQ:MOBL) are the two most active stocks in the Biotechnology industry based on todays trading volumes. Investors are clearly interested in the two names, but is one a better choice than the other? We will compare the two companies across growth, profitability, risk, valuation, and insider trends to answer this question.
Companies that can consistently grow earnings at a high compound rate usually have the greatest potential to create value for shareholders in the long-run. Analysts expect XON to grow earnings at a 42.50% annual rate over the next 5 years.
A high growth rate isnt necessarily valuable to investors. In fact, companies that overinvest in low return projects just to achieve a high growth rate can actually destroy shareholder value. Profitability and returns are a measure of the quality of a companys business and its growth opportunities. Well use Return on Investment (ROI) to measure this. XONs ROI is -84.20% while MOBL has a ROI of -81.70%. The interpretation is that MOBLs business generates a higher return on investment than XONs.
If theres one thing investors care more about than earnings, its cash flow. XONs free cash flow (FCF) per share for the trailing twelve months was -0.31. Comparatively, MOBLs free cash flow per share was -0.06. On a percent-of-sales basis, XONs free cash flow was -0.03% while MOBL converted -0% of its revenues into cash flow. This means that, for a given level of sales, MOBL is able to generate more free cash flow for investors.
Liquidity and leverage ratios measure a companys ability to meet short-term obligations and longer-term debts. XON has a current ratio of 3.50 compared to 1.30 for MOBL. This means that XON can more easily cover its most immediate liabilities over the next twelve months. XONs debt-to-equity ratio is 0.92 versus a D/E of 0.00 for MOBL. XON is therefore the more solvent of the two companies, and has lower financial risk.
XON trades at a P/B of 3.08, and a P/S of 6.87, compared to a forward P/E of 166.21, a P/B of 13.39, and a P/S of 2.70 for MOBL. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.
Analyst Price Targets and Opinions
Just because a stock is cheaper doesnt mean theres more value to be had. In order to assess value we need to compare the current price to where its likely to trade in the future. XON is currently priced at a -41.99% to its one-year price target of 9.67. Comparatively, MOBL is -33.97% relative to its price target of 7.30. This suggests that XON is the better investment over the next year.
Risk and Volatility
No discussion on value is complete without taking into account risk. Analysts use a stocks beta, which measures the volatility of a stock compared to the overall market, to measure systematic risk. A stock with a beta above 1 is more volatile than the market. Conversely, a beta below 1 implies a below average level of risk. XON has a beta of 2.25 and MOBLs beta is 1.60. MOBLs shares are therefore the less volatile of the two stocks.
Short interest is another tool that analysts use to gauge investor sentiment. It represents the percentage of a stocks tradable shares that are being shorted. XON has a short ratio of 33.75 compared to a short interest of 2.21 for MOBL. This implies that the market is currently less bearish on the outlook for MOBL.
MobileIron, Inc. (NASDAQ:MOBL) beats Intrexon Corporation (NASDAQ:XON) on a total of 8 of the 14 factors compared between the two stocks. MOBL is growing fastly, has higher cash flow per share, has a higher cash conversion rate and has lower financial risk. Finally, MOBL has better sentiment signals based on short interest.